WHAT IS CLAIMED IS:

1. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for treating bronchiectasis in a subject in need thereof.

2. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for improving pre-bronchodilator forced expiratory volume 1 (FEV_1) in a subject with bronchiectasis.

3. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for reducing *Pseudomonas aeruginosa* load in a subject with bronchiectasis.

4. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for reducing bronchiectasis exacerbations in a subject in need thereof.

5. The use of claim 4, wherein the medicament is capable of reducing bronchiectasis exacerbations requiring hospitalization.

6. The use of claim 4 or 5, wherein the medicament is capable of reducing bronchiectasis exacerbations requiring antibiotics.

7. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for reducing the need for intravenous antibiotics in a subject with bronchiectasis.

8. Use of a bispecific antibody that is capable of specifically binding to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide in the manufacture of a medicament for stabilizing lung function in a subject with bronchiectasis.

9. The use of any one of claims 1-8, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis.

10. The use of claim 9, wherein the non-cystic fibrosis bronchiectasis was confirmed by chest computed tomography (CT) demonstrating bronchiectasis affecting 1 or more lobes.

11. The use of any one of claims 1-10, wherein the subject is colonized with *Pseudomonas aeruginosa*.

12. The use of claim 11, wherein the *Pseudomonas aeruginosa* colonization has been detected by sputum culture.

13. The use of any one of claims 1-12, wherein the subject is chronically infected with *Pseudomonas aeruginosa*.

14. The use of any one of claims 1-13, wherein the subject has airway neutrophilia.

15. The use of any one of claims 1-14, wherein the subject has sputum neutrophilia.

16. The use of any one of claims 1-15, wherein the subject has a history of at least 2 moderate to severe bronchiectasis exacerbations per year requiring antibiotics.

17. The use of any one of claims 1-16, wherein the subject has a history of at least 1 exacerbation requiring hospital care.

18. The use of any one of claims 1-17, wherein the subject is on long term nebulized antibiotics.

19. The use of any one of claims 1-18, wherein the subject has chronic obstructive pulmonary disease (COPD).

20. The use of any one of claims 1-19, wherein the bronchiectasis was caused by hypogammaglobulinemia.

21. The use of any one of claims 1-19, wherein the bronchiectasis was caused by common variable immunodeficiency.

22. The use of any one of claims 1-19, wherein the bronchiectasis was caused by alpha-1-antitrypsin deficiency.

23. The use of any one of claims 1-22, wherein the administration is capable of reducing *Pseudomonas aeruginosa* in sputum cultures obtained from the subject.

24. The use of any one of claims 1-23, wherein the administration is capable of decreasing antibiotic usage.

25. The use of any one of claims 1-24, wherein the administration is capable of eradicating *Pseudomonas aeruginosa* in the subject.

26. The use of any one of claims 1-25, wherein the bispecific antibody is capable of competitively inhibiting binding to PcrV of an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:14.

27. The use of any one of claims 1-26, wherein the bispecific antibody is capable of binding to the same epitope of PcrV as an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:14.

28. The use of any one of claims 1-27, wherein the bispecific antibody comprises a PcrV-binding domain comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.

29. The use of any one of claims 1-28, wherein the bispecific antibody comprises a PcrV-binding domain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:14.

30. The use of any one of claims 1-29, wherein the bispecific antibody comprises a PcrV-binding domain with a heavy chain variable region and a light chain variable region on separate polypeptides.

31. The use of any one of claims 1-30, wherein the bispecific antibody is capable of competitively inhibiting binding to Psl of an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:16.

32. The use of any one of claims 1-31, wherein the bispecific antibody is capable of binding to the same epitope of Psl as an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:16.

33. The use of any one of claims 1-32, wherein the bispecific antibody comprises a Psl-binding domain comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:8, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:9, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:12.

34. The use of any one of claims 1-33, wherein the bispecific antibody comprises a Psl-binding domain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15 and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:16.

35. The use of any one of claims 1-34, wherein the bispecific antibody comprises a Psl-binding domain with a heavy chain variable region and a light chain variable region on the same polypeptide.

36. The use of any one of claims 1-35, wherein the bispecific antibody comprising a Psl-binding domain that is an scFv.

37. The use of claim 36, wherein the scFv comprises a linker.

38. The use of claim 37, wherein the linker comprises the amino acid sequence of SEQ ID NO:18.

39. The use of claim 37 or 38, wherein the scFv is in the orientation VH-linker-VL.

40. The use of any one of claims 36-39, wherein the scFv comprises the amino acid sequence of SEQ ID NO:17.

41. The use of any one of claims 1-40, wherein the bispecific antibody is an IgG antibody.

42. The use of any one of claims 1-41, wherein the bispecific antibody comprises (i) a heavy chain of the formula VH-CH1-H1-L1-S-L2-H2-CH2-CH3, wherein VH is an anti-*P. aeruginosa* PcrV heavy chain variable domain; CH1 is a heavy chain constant region domain 1; H1 is a first heavy chain hinge region fragment; L1 is a first linker; S is an anti-*P. aeruginosa* Psl scFv molecule; L2 is a second linker; H2 is a second heavy chain hinge region fragment; CH2 is a heavy chain constant region domain-2; and CH3 is a heavy chain constant region domain-3; and (ii) a light chain of the formula VL-CL, wherein VL is an anti-*P. aeruginosa* PcrV light chain variable domain, and CL is an antibody light chain kappa constant region or an antibody light chain lambda region.

43. The use of claim 42, wherein the VH comprises the amino acid sequence of SEQ ID NO:13, the scFv comprises the amino acid sequence of SEQ ID NO:15 and the amino acid sequence of SEQ ID NO:16, and/or the VL comprises the amino acid sequence of SEQ ID NO:14.

44. The use of claim 42, wherein the VH comprises the amino acid sequence of SEQ ID NO:13, the scFv comprises the amino acid sequence of SEQ ID NO:17, and/or the VL comprises the amino acid sequence of SEQ ID NO:14.

45. The use of any one of claims 42-44, wherein CL is an antibody light chain kappa constant region.

46. The use of any one of claims 1-45, wherein the bispecific antibody is capable of neutralizing cellular intoxication.

47. The use of any one of claims 1-46, wherein the bispecific antibody is capable of targeting *Pseudomonas aeruginosa* for opsonophagocytic killing.

48. The use of any one of claims 1-47, wherein the bispecific antibody is capable of preventing cell attachment.

49. The use of any one of claims 1-48, wherein the bispecific antibody is capable of disrupting biofilm formation.

50. The use of any one of claims 1-49, wherein the subject is colonized with a *Pseudomonas aeruginosa* strain comprising a genome comprising a Psl-operon.

51. The use of any one of claims 1-50, wherein the subject is colonized with a *Pseudomonas aeruginosa* strain comprising a genome comprising a PcrV-encoding loci.

52. The use of any one of claims 1-51, wherein the medicament is suitable for intravenous administration.

53. The use of any one of claims 1-51, wherein the medicament is suitable for subcutaneous administration.

54. The use of any one of claims 1-53, further comprising use of an antibiotic.

55. The use of any one of claims 1-54, wherein the subject is human.